| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
VV116 (JT001) 是一种具有口服活性的核苷类抗病毒剂，可抵抗 SARS-CoV-2 和呼吸道合胞病毒 (RSV) 感染。VV116 具有良好的口服生物利用度、良好的体外抗病毒活性和选择性。
| 别名 | JT001; GS-621763-d1 hydrobromide |
| 分子式 | C24H31DBrN5O7 |
| 分子量 | 583.45 |
| 溶解度 | DMSO : 250 mg/mL (428.49 mM; Need ultrasonic) |
| 储存条件 | 4°C, away from moisture |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | VV116 (JT001) is an orally active nucleoside antiviral agent against SARS-CoV-2 and respiratory syncytial virus (RSV) infection. VV116 has favorable oral bioavailability, excellent in vitro antiviral activity and selectivity[1][2]. VV116 (0-1000 μM; 48 hours) can inhibit RSV replication in A549 cells[1]. VV116 (25, 50 and 100 mg/kg; PO; b.i.d for 4 days) exhibits a stronger activity and decreases the virus titers below the detection limit at 50 mg/kg, also reduces lung injury after RSV infection[1].VV116 (25, 50 and 100 mg/kg; PO; single dosage) exhibits favorable PK properties and good safety profile[1].Pharmacokinetic Parameters of VV116 (JT001) in Balb/c mice[1]. PO (25 mg/kg) PO (50 mg/kg) PO (100 mg/kg) Tmax (h)0.42 ± 0.140.42 ± 0.140.42 ± 0.14Cmax (ng/mL)5360 ± 56011617 ± 344324017 ± 6521AUC0-t (ng/mL.h)11461 ± 101324594 ± 105947799 ± 6545 AUC0-∞ (ng/mL.h)11534 ± 99224739 ± 102848014 ± 6696MRT0-∞ (ng/mL.h)2.25 ± 0.322.15 ± 0.262.28 ± 0.53Tmax (h)2.30 ± 1.103.27 ± 1.924.25 ± 0.53 [1]. Zhang R, et al. Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model. Signal Transduct Target Ther. 2022;7(1):123. Published 2022 Apr 16. |
m.cnreagent.com